Aktie A3C2CC STATERA BIOPHARMA, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Statera Biopharma, Inc. Nasdaq

Aktien

A3C2CC

US8575611046

STAB

Verzögert Nasdaq
Andere Börsenplätze
 16:01:15 17.05.2024 		% 5 Tage % 1. Jan.
0.0007 USD 0.00% Intraday Chart für Statera Biopharma, Inc. 0.00% -99.98%
2022 Statera Biopharma, Inc. meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 30. September 2022 CI
2022 Statera Biopharma, Inc. meldet Ergebnis für das zweite Quartal und die sechs Monate bis zum 30. Juni 2022 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs.
STATERA BIOPHARMA, INC. : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
STATERA BIOPHARMA, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K)
Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index
Statera Biopharma, Inc.(OTCPK:STAB) dropped from NASDAQ Composite Index
STATERA BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
STATERA BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Statera Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Statera Biopharma : Material Agreement - Form 8-K
STATERA BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
Statera Biopharma, Inc. announced that it has received $0.4 million in funding from Silverback Capital Corporation
Statera Biopharma, Inc. announced that it expects to receive $0.765 million in funding
STATERA BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Statera Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
STATERA BIOPHARMA, INC. : Other Events (form 8-K)
STATERA BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
STATERA BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Statera Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
US Futures Lower Amid Earnings Reports, Ahead of Flash PMI Data
Top Premarket Gainers
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. STAB Aktie
  4. A3C2CC Aktie
  5. Nachrichten Statera Biopharma, Inc.
  6. Andere Sprachen